{
    "organizations": [],
    "uuid": "e7abd11c1600cb7bedde5e7311a8cad1e7f97040",
    "author": "",
    "url": "https://www.reuters.com/article/brief-alder-says-eptinezumab-met-primary/brief-alder-says-eptinezumab-met-primary-endpoint-in-pivotal-phase-3-promise-2-clinical-trial-idUSASB0C02C",
    "ord_in_thread": 0,
    "title": "BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / Updated 14 minutes ago BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial Reuters Staff 1 Min Read \nJan 8 (Reuters) - Alder Biopharmaceuticals Inc: \n* ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION \n* ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL \n* ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​ \n* ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE \n* ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​ \n* ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018  ",
    "published": "2018-01-08T14:39:00.000+02:00",
    "crawled": "2018-01-08T15:01:01.100+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "eptinezumab",
        "met",
        "primary",
        "endpoint",
        "pivotal",
        "phase",
        "promise",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "alder",
        "biopharmaceuticals",
        "inc",
        "alder",
        "announces",
        "eptinezumab",
        "significantly",
        "reduces",
        "migraine",
        "risk",
        "meet",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "pivotal",
        "promise",
        "phase",
        "trial",
        "chronic",
        "migraine",
        "prevention",
        "alder",
        "biopharmaceuticals",
        "inc",
        "announced",
        "eptinezumab",
        "met",
        "primary",
        "endpoint",
        "pivotal",
        "phase",
        "promise",
        "clinical",
        "trial",
        "alder",
        "biopharmaceuticals",
        "inc",
        "patient",
        "migraine",
        "full",
        "three",
        "alder",
        "biopharmaceuticals",
        "inc",
        "addition",
        "eptinezumab",
        "met",
        "key",
        "secondary",
        "endpoint",
        "high",
        "statistical",
        "significance",
        "alder",
        "biopharmaceuticals",
        "inc",
        "tolerability",
        "similar",
        "previously",
        "reported",
        "eptinezumab",
        "alder",
        "biopharmaceuticals",
        "inc",
        "plan",
        "submit",
        "bla",
        "fda",
        "eptinezumab",
        "h2"
    ]
}